New clinical trial to explore effects of omega-3 fatty acids and vitamin D in type 1 diabetes

July 11, 2018, Diabetes Research Institute Foundation
New type 1 Diabetes clinical trial explores effects of Omega-3 and Vitamin D
Credit: Diabetes Research Institute Foundation

Scientists from the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine today announced the launch of a new clinical trial that will assess the impact of high-dose omega-3 fatty acids and vitamin D supplementation on halting the progression of type 1 diabetes (T1D). The DRI has received FDA IND clearance to proceed with the Phase I/IIa trial, named the POSEIDON Study (Pilot study of Omega-3 and Vitamin D High Doses in T1D), to compare the effects of the proposed intervention in children and adults newly diagnosed and in those with longer-standing T1D to evaluate any benefit of early and late interventions.

Several scientific reports have suggested that the use of high-dose omega-3 and vitamin D, both of which have known anti-inflammatory and immunomodulatory properties, may offer a potential beneficial effect on autoimmune conditions, like type 1 . DRI researchers hypothesize that the treatment may delay or forestall the disease.

"My impetus for starting this study is to determine if modulating inflammation and immunity could halt, or at least delay, the progression of type 1 diabetes. Inflammation may be one of the triggers for autoimmunity that leads to the onset of the disease, but also has an effect on insulin resistance and, therefore, islet dysfunction," said Camillo Ricordi, M.D., study sponsor and Director of the Diabetes Research Institute at the Miller School of Medicine. "Results from our recent case studies examining the role of omega-3/vitamin D in preserving beta cell function in three pediatric subjects with type 1 diabetes warrant further investigation of this potential therapeutic strategy," continued Dr. Ricordi, referring to his recent findings in collaboration with Italian centers in Rome and Novara, including those published in European Review for Medical and Pharmacological Sciences.

The DRI plans to enroll 56 adults and children in the two-arm, open-label study. The investigators will compare children and adults with type 1 diabetes, both newly diagnosed and those more than six months post-diagnosis, who take either vitamin D alone or in combination with . The participants will be treated for one year, followed by a one-year observation period to measure any long-term effect on blood sugar control, increase in endogenous insulin production, and other outcomes.

Diabetes Research Institute Director Camillo Ricordi, M.D., explains the new POSEIDON clinical study, which will assess the impact of high-dose omega-3 fatty acids and vitamin D supplementation on blocking the progression of type 1 diabetes or treating established diabetes in both children and adults. Credit: Diabetes Research Institute Foundation

Participants will be randomized to either 25-hydroxyvitamin D (cholecalciferol) alone, or in combination with ultra-refined omega-3 EPA/DHA derived from fish oil. Although initial dosing will be based on factors like age and body weight, investigators will monitor and adjust vitamin D dosing every four months. They will also adjust the omega-3 fatty acids dosage based on monthly monitoring of the ratio of arachidonic acid to eicosapentaenoic acid (AA/EPA).

A higher AA/EPA ratio is considered detrimental because AA is thought to promote inflammation and decrease the regulatory cells that could protect against autoimmunity, whereas EPA can be protective. More EPA could improve other conditions where inflammation plays a key role.

"Reversing autoimmunity could be beneficial well beyond subjects with type 1 diabetes. In fact, similar strategies should be tested in other autoimmune diseases like Crohn's, rheumatoid arthritis and lupus erythematous," Dr. Ricordi said.

All participants will receive standard diabetes treatment with insulin and dietary control.

"If combination omega-3 and vitamin D therapy is able to delay progression or halt autoimmunity in type 1 diabetes, this is expected to result in retention of insulin secretion, minimal use of exogenous insulin, and improved metabolic control thus minimizing the risks associated with unstable blood glucose levels," Dr. Ricordi said.

Explore further: Omega-3 fatty acid supplementation may treat autoimmunity in type 1 diabetes

Related Stories

Omega-3 fatty acid supplementation may treat autoimmunity in type 1 diabetes

April 4, 2017
Type I diabetes (T1D) is an autoimmune condition that develops after the immune system attacks and destroys pancreatic β cells, leading to impaired insulin production. Currently, no therapies can successfully reverse the ...

Study suggests omega-3 in mothers' diets may lower children's risk of type 1 diabetes

May 4, 2017
New research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]) suggests that omega 3 polyunsaturated fatty acids (PUFAs), derived primarily from fish in maternal diet during ...

Enough vitamin D when young associated with lower risk of diabetes-related autoimmunity

October 23, 2017
Getting enough vitamin D during infancy and childhood is associated with a reduced risk of islet autoimmunity among children at increased genetic risk for type 1 diabetes, according to a study published this week in the journal ...

Vitamin D doesn't impact insulin sensitivity, secretion in T2DM

May 10, 2017
(HealthDay)—For patients with type 2 diabetes (T2D) and vitamin D deficiency, vitamin D supplementation has no impact on insulin sensitivity or secretion, according to a study published online May 3 in Diabetes Care.

High serum omega-6 polyunsaturated fatty acid concentrations linked to lower risk of type 2 diabetes

March 24, 2016
A new study from the University of Eastern Finland shows that high serum omega-6 polyunsaturated fatty acid concentrations are linked to a significantly reduced risk of type 2 diabetes. The findings were published in the ...

High omega-6 levels can protect against premature death

March 19, 2018
Could omega-6 fatty acids protect you against premature death? The answer is yes, according to a new University of Eastern Finland study. While protecting against death, omega-6 fatty acids also keep cardiovascular diseases ...

Recommended for you

Can't exercise? A hot bath may help improve inflammation, metabolism, study suggests

November 14, 2018
Hot water treatment may help improve inflammation and blood sugar (glucose) levels in people who are unable to exercise, according to a new study. The findings are published ahead of print in the Journal of Applied Physiology.

Diabetic foot ulcers heal quickly with nitric oxide technology

November 12, 2018
Diabetic foot ulcers can take up to 150 days to heal. A biomedical engineering team wants to reduce it to 21 days.

Diabetes drug might also ease heart failure risks

November 12, 2018
(HealthDay)—The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows.

Marijuana use tied to serious diabetes complication

November 8, 2018
(HealthDay)—People with type 1 diabetes who use marijuana may double their risk of developing a life-threatening complication, a new study suggests.

Researchers report connection between intestinal bacteria and development of diabetes

November 7, 2018
Researchers at Örebro University have, together with a well-known research team in Denmark, developed a method for studying how metabolism in gut bacteria influences health. Their method will now be published in its entirety ...

Genetic factors tied to obesity may protect against diabetes

November 2, 2018
Some genetic variations linked with obesity actually protect against Type 2 diabetes, heart attack and stroke, new findings suggest.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.